Hyperpolarized 129Xe ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 86 | 肺動脈性肺高血圧症 | 1 |
86. 肺動脈性肺高血圧症
臨床試験数 : 1,181 / 薬物数 : 701 - (DrugBank : 126) / 標的遺伝子数 : 105 - 標的パスウェイ数 : 192
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04778046 (ClinicalTrials.gov) | February 15, 2022 | 26/2/2021 | Pulmonary Hypertension SOLAR | Defining a Noninvasive Signature for Pulmonary Vascular Remodeling in Group 3 PH | Interstitial Lung Disease;COPD;Pulmonary Arterial Hypertension | Drug: Hyperpolarized 129Xe | Bastiaan Driehuys | NULL | Not yet recruiting | 18 Years | N/A | All | 30 | Phase 2 | United States |